# AgEagle Aerial Systems Inc.: financial statements, quarterly

UAVS · NYSE · CIK 8504 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uavs.md) · [Financials](/companies/uavs/financials.md) · [Filings](/companies/uavs/filings.md) · [Insiders](/companies/uavs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uavs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.5](/filings/0001493152-24-046810.md) | [2.9 d](/filings/0001641172-25-001563.md) | [3.9](/filings/0001641172-25-010884.md) | [3.4](/filings/0001493152-24-032001.md) | [3.3](/filings/0001493152-24-046810.md) | [2.8 d](/filings/0001641172-25-001563.md) | [3.6](/filings/0001641172-25-010884.md) | [4.2](/filings/0001437749-26-028026.md) | [2.0](/filings/0001437749-25-035221.md) | [3.0 d](/filings/0001437749-26-010682.md) | [1.4](/filings/0001437749-26-017229.md) | [2.7](/filings/0001437749-26-028026.md) |
| Cost of revenue | $m | [2.3](/filings/0001493152-24-046810.md) | [1.7 d](/filings/0001641172-25-001563.md) | [1.9](/filings/0001641172-25-010884.md) | [1.8](/filings/0001437749-25-026927.md) | [1.7](/filings/0001437749-25-035221.md) | [1.7 d](/filings/0001437749-26-010682.md) | [1.5](/filings/0001437749-26-017229.md) | [1.9](/filings/0001437749-26-028026.md) | [1.2](/filings/0001437749-25-035221.md) | [1.6 d](/filings/0001437749-26-010682.md) | [0.8](/filings/0001437749-26-017229.md) | [1.3](/filings/0001437749-26-028026.md) |
| Gross profit | $m | [1.2](/filings/0001493152-24-046810.md) | [1.2 d](/filings/0001641172-25-001563.md) | [2.0](/filings/0001641172-25-010884.md) | [1.6](/filings/0001437749-25-026927.md) | [1.6](/filings/0001437749-25-035221.md) | [1.1 d](/filings/0001437749-26-010682.md) | [2.1](/filings/0001437749-26-017229.md) | [2.3](/filings/0001437749-26-028026.md) | [0.8](/filings/0001437749-25-035221.md) | [1.4 d](/filings/0001437749-26-010682.md) | [0.6](/filings/0001437749-26-017229.md) | [1.4](/filings/0001437749-26-028026.md) |
| Research and development | $m | [1.4](/filings/0001493152-24-046810.md) | [1.2 d](/filings/0001641172-25-001563.md) | [1.1](/filings/0001641172-25-010884.md) | [1.1](/filings/0001437749-25-026927.md) | [1.0](/filings/0001437749-25-035221.md) | [0.8 d](/filings/0001437749-26-010682.md) | [0.7](/filings/0001437749-26-017229.md) | [0.8](/filings/0001437749-26-028026.md) | [1.0](/filings/0001437749-25-035221.md) | [1.1 d](/filings/0001437749-26-010682.md) | [1.8](/filings/0001437749-26-017229.md) | [2.0](/filings/0001437749-26-028026.md) |
| Operating income | $m | [(6.0)](/filings/0001493152-24-046810.md) | [(24.1) d](/filings/0001641172-25-001563.md) | [(2.4)](/filings/0001641172-25-010884.md) | [(2.5)](/filings/0001437749-25-026927.md) | [(1.9)](/filings/0001437749-25-035221.md) | [(5.8) d](/filings/0001437749-26-010682.md) | [(1.0)](/filings/0001437749-26-017229.md) | [(2.1)](/filings/0001437749-26-028026.md) | [(3.2)](/filings/0001437749-25-035221.md) | [(8.5) d](/filings/0001437749-26-010682.md) | [(5.1)](/filings/0001437749-26-017229.md) | [(5.6)](/filings/0001437749-26-028026.md) |
| Interest expense | $m | [0.1](/filings/0001493152-23-040239.md) | [(0.1) d](/filings/0001493152-24-047969.md) | [0.1](/filings/0001641172-25-010884.md) | [0.3](/filings/0001437749-25-026927.md) | [1.6](/filings/0001437749-25-035221.md) | [(4.8) d](/filings/0001641172-25-001563.md) | [0.0](/filings/0001641172-25-010884.md) | [0.0](/filings/0001437749-25-026927.md) | [0.0](/filings/0001437749-25-035221.md) | [(0.1) d](/filings/0001437749-26-010682.md) | [(0.2)](/filings/0001437749-26-017229.md) | not reported |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001437749-25-026927.md) | [0.0](/filings/0001437749-25-035221.md) | [0.0 d](/filings/0001437749-26-010682.md) | [0.0](/filings/0001437749-26-017229.md) | [0.0](/filings/0001437749-26-028026.md) | [0.0](/filings/0001437749-25-035221.md) | [0.0 d](/filings/0001437749-26-010682.md) | [0.0](/filings/0001437749-26-017229.md) | [0.0](/filings/0001437749-26-028026.md) |
| Net income | $m | [(8.0)](/filings/0001493152-24-046810.md) | [(24.5) d](/filings/0001641172-25-001563.md) | [(6.3)](/filings/0001641172-25-010884.md) | [(2.9)](/filings/0001437749-25-026927.md) | [(3.5)](/filings/0001437749-25-035221.md) | [(22.3) d](/filings/0001437749-26-010682.md) | [7.1](/filings/0001437749-26-017229.md) | [(1.3)](/filings/0001437749-26-028026.md) | [(2.6)](/filings/0001437749-25-035221.md) | [(8.4) d](/filings/0001437749-26-010682.md) | [1.4](/filings/0001437749-26-017229.md) | [(15.4)](/filings/0001437749-26-028026.md) |
| Diluted EPS | $ per share | [(1.45)](/filings/0001493152-24-047969.md) | not reported | [(70.50)](/filings/0001641172-25-010884.md) | [(12.06)](/filings/0001437749-25-026927.md) | [(16.03)](/filings/0001437749-25-035221.md) | not reported | [(0.09)](/filings/0001437749-26-017229.md) | [(0.32)](/filings/0001437749-26-028026.md) | [(0.09)](/filings/0001437749-25-035221.md) | not reported | [0.00](/filings/0001437749-26-017229.md) | [(0.26)](/filings/0001437749-26-028026.md) |
| Basic EPS | $ per share | [(1.45)](/filings/0001493152-24-047969.md) | not reported | [(70.50)](/filings/0001641172-25-010884.md) | [(12.06)](/filings/0001437749-25-026927.md) | [(16.03)](/filings/0001437749-25-035221.md) | not reported | [0.51](/filings/0001437749-26-017229.md) | [(0.32)](/filings/0001437749-26-028026.md) | [(0.09)](/filings/0001437749-25-035221.md) | not reported | [0.00](/filings/0001437749-26-017229.md) | [(0.26)](/filings/0001437749-26-028026.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.6](/filings/0001493152-23-040239.md) | [0.8](/filings/0001641172-25-001563.md) | [0.8](/filings/0001493152-24-019782.md) | [1.0](/filings/0001493152-24-032001.md) | [0.3](/filings/0001493152-24-046810.md) | [3.6](/filings/0001641172-25-010884.md) | [3.8](/filings/0001641172-25-010884.md) | [5.5](/filings/0001437749-25-026927.md) | [16.6](/filings/0001437749-25-035221.md) | [29.9](/filings/0001437749-26-028026.md) | [26.9](/filings/0001437749-26-017229.md) | [15.9](/filings/0001437749-26-028026.md) |
| Current assets | $m | [10.7](/filings/0001493152-23-040239.md) | [10.5](/filings/0001641172-25-001563.md) | [9.3](/filings/0001493152-24-019782.md) | [9.4](/filings/0001493152-24-032001.md) | [8.8](/filings/0001493152-24-046810.md) | [10.9](/filings/0001437749-26-010682.md) | [11.0](/filings/0001641172-25-010884.md) | [14.1](/filings/0001437749-25-026927.md) | [25.8](/filings/0001437749-25-035221.md) | [39.5](/filings/0001437749-26-028026.md) | [43.5](/filings/0001437749-26-017229.md) | [28.1](/filings/0001437749-26-028026.md) |
| Total assets | $m | [46.1](/filings/0001493152-23-040239.md) | [25.2](/filings/0001641172-25-001563.md) | [23.2](/filings/0001493152-24-019782.md) | [22.8](/filings/0001493152-24-032001.md) | [22.0](/filings/0001493152-24-046810.md) | [20.6](/filings/0001437749-26-010682.md) | [20.2](/filings/0001641172-25-010884.md) | [23.2](/filings/0001437749-25-026927.md) | [34.5](/filings/0001437749-25-035221.md) | [42.2](/filings/0001437749-26-028026.md) | [48.1](/filings/0001437749-26-017229.md) | [37.9](/filings/0001437749-26-028026.md) |
| Current liabilities | $m | [7.9](/filings/0001493152-23-040239.md) | [11.0](/filings/0001641172-25-001563.md) | [11.3](/filings/0001493152-24-019782.md) | [12.2](/filings/0001493152-24-032001.md) | [13.4](/filings/0001493152-24-046810.md) | [7.9](/filings/0001437749-26-010682.md) | [5.6](/filings/0001641172-25-010884.md) | [5.0](/filings/0001437749-25-026927.md) | [4.5](/filings/0001437749-25-035221.md) | [5.0](/filings/0001437749-26-028026.md) | [4.4](/filings/0001437749-26-017229.md) | [4.4](/filings/0001437749-26-028026.md) |
| Total liabilities | $m | [12.6](/filings/0001493152-23-040239.md) | [14.5](/filings/0001641172-25-001563.md) | [14.2](/filings/0001493152-24-019782.md) | [14.8](/filings/0001493152-24-032001.md) | [15.8](/filings/0001493152-24-046810.md) | [26.3](/filings/0001437749-26-010682.md) | [16.0](/filings/0001641172-25-010884.md) | [6.9](/filings/0001437749-25-026927.md) | [6.1](/filings/0001437749-25-035221.md) | [6.5](/filings/0001437749-26-028026.md) | [7.3](/filings/0001437749-26-017229.md) | [7.0](/filings/0001437749-26-028026.md) |
| Long-term debt | $m | [0.5](/filings/0001493152-23-040239.md) | [0.5](/filings/0001641172-25-001563.md) | [0.4](/filings/0001493152-24-019782.md) | [0.3](/filings/0001493152-24-032001.md) | [0.3](/filings/0001493152-24-046810.md) | [0.3](/filings/0001437749-26-010682.md) | [0.2](/filings/0001641172-25-010884.md) | [0.2](/filings/0001437749-25-026927.md) | [0.2](/filings/0001437749-25-035221.md) | [0.2](/filings/0001437749-26-028026.md) | [0.2](/filings/0001437749-26-017229.md) | [0.2](/filings/0001437749-26-028026.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | [0.7](/filings/0001493152-24-019782.md) | [1.1](/filings/0001493152-24-032001.md) | [0.8](/filings/0001493152-24-046810.md) | [0.1](/filings/0001437749-26-010682.md) | not reported | [0.0](/filings/0001437749-25-026927.md) | [0.0](/filings/0001437749-25-035221.md) | [0.0](/filings/0001437749-26-010682.md) | not reported | not reported |
| Shareholders' equity | $m | [33.4](/filings/0001493152-24-046810.md) | [10.7](/filings/0001437749-26-010682.md) | [9.1](/filings/0001437749-25-026927.md) | [8.1](/filings/0001437749-25-035221.md) | [6.2](/filings/0001437749-25-035221.md) | [(5.7)](/filings/0001437749-26-028026.md) | [4.2](/filings/0001437749-26-028026.md) | [16.3](/filings/0001437749-26-028026.md) | [28.3](/filings/0001437749-25-035221.md) | [35.7](/filings/0001437749-26-028026.md) | [40.9](/filings/0001437749-26-028026.md) | [30.9](/filings/0001437749-26-028026.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,046) d](/filings/0001493152-24-046810.md) | [(2,127) d](/filings/0001641172-25-001563.md) | [(1,553)](/filings/0001641172-25-010884.md) | [(1,430) d](/filings/0001437749-25-026927.md) | [(1,073) d](/filings/0001437749-25-035221.md) | [(2,515) d](/filings/0001437749-26-010682.md) | [(1,295)](/filings/0001437749-26-017229.md) | [(2,745) d](/filings/0001437749-26-028026.md) | [(3,295) d](/filings/0001437749-25-035221.md) | [(2,623) d](/filings/0001437749-26-010682.md) | [(2,360)](/filings/0001437749-26-017229.md) | [(6,012) d](/filings/0001437749-26-028026.md) |
| Capital expenditure | $k | [46.9 d](/filings/0001493152-24-046810.md) | [120 d](/filings/0001641172-25-001563.md) | [22.4](/filings/0001641172-25-010884.md) | [12.3 d](/filings/0001437749-25-026927.md) | [0.3 d](/filings/0001437749-25-035221.md) | [14.5 d](/filings/0001437749-26-010682.md) | [10.4](/filings/0001437749-26-017229.md) | [13.5 d](/filings/0001437749-26-028026.md) | [14.5 d](/filings/0001437749-25-035221.md) | [36.3 d](/filings/0001437749-26-010682.md) | [357](/filings/0001437749-26-017229.md) | [198 d](/filings/0001437749-26-028026.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-017229.md) | [0.0 d](/filings/0001437749-26-028026.md) | not reported | not reported | [854](/filings/0001437749-26-017229.md) | [51.0 d](/filings/0001437749-26-028026.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [114](/filings/0001493152-23-040239.md) | [4.5](/filings/0001493152-24-019782.md) | [4.8](/filings/0001493152-24-032001.md) | [0.1](/filings/0001493152-24-046810.md) | [0.2](/filings/0001641172-25-010884.md) | [0.2](/filings/0001437749-25-026927.md) | [0.3](/filings/0001437749-25-035221.md) | [20.2](/filings/0001437749-26-017229.md) | [15.5](/filings/0001437749-26-028026.md) | [32.2](/filings/0001437749-25-035221.md) | [57.2](/filings/0001437749-26-017229.md) | [59.6](/filings/0001437749-26-028026.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,905,706 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-028026.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.